Mindbio completes phase 2B dosing of depression trial

Executive Summary

• Mindbio Therapeutics Corp. has completed dosing in its landmark Phase 2B microdosing clinical trial for Major Depressive Disorder (MDD) using its lead candidate, MB22001.
• The trial utilized a unique take-home, self-dosing model for a psychedelic medicine (LSD microdose), marking a world-first regulatory approval for such a protocol.
• Positive results from this trial are expected to position Mindbio as the developer of the most advanced take-home psychedelic medicine and inform progression toward Phase 3 trials and potential commercialization.

Key Details

• Trial Completion: Dosing for the Phase 2B trial has been completed.
• Drug Candidate: MB22001, a proprietary, titratable microdose formulation of lysergic acid diethylamide (LSD).
• Trial Design: Triple-blind, double-dummy, active placebo-controlled trial.
• Patient Population: 90 patients diagnosed with Major Depressive Disorder (MDD).
• Key Differentiator: The trial represents a "world first" for receiving regulatory approval for the take-home use of a psychedelic medicine. The microdoses are subhallucinogenic, allowing patients to self-administer without supervision or disruption to daily activities.
• Strategic Implications: Results will inform decisions regarding progression to post-Phase 2B commercialization (early and special access programs) and Phase 3 clinical trials.
• Company Positioning: Mindbio claims to be the only psychedelic medicine development company to have substantially and successfully tested a take-home dosing protocol in randomized controlled trials for several years.
• Next Steps: The company expects to present the results of this trial shortly.

Notable Quotes

• "This is a pivotal moment for Mindbio as we progress the development of novel treatments for psychiatric conditions towards commercialization. We look forward to presenting the results of this important clinical trial which is expected shortly." — Justin Hanka, Chief Executive Officer